sarcosine has been researched along with Prostatic Hyperplasia in 3 studies
cocobetaine: N-alkyl-betaine; cause of shampoo dermatitis
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Plasma sarcosine was measured using gas chromatography-mass spectrometry (GC-MS) in adults classified as noncancerous controls (with benign prostate hyperplasia [BPH], n = 36), with prostatic intraepithelial neoplasia (PIN, n = 16), or with PCa (n = 27)." | 7.96 | Plasma Sarcosine Measured by Gas Chromatography-Mass Spectrometry Distinguishes Prostatic Intraepithelial Neoplasia and Prostate Cancer from Benign Prostate Hyperplasia. ( Appolonova, SA; Brito, A; Enikeev, DV; Fodor, M; Lartsova, EV; Lerner, YV; Lyundup, AV; Markin, PA; Mikhajlov, VY; Moskaleva, N; Potoldykova, NV; Shpot, YV, 2020) |
| "Plasma sarcosine was measured using gas chromatography-mass spectrometry (GC-MS) in adults classified as noncancerous controls (with benign prostate hyperplasia [BPH], n = 36), with prostatic intraepithelial neoplasia (PIN, n = 16), or with PCa (n = 27)." | 3.96 | Plasma Sarcosine Measured by Gas Chromatography-Mass Spectrometry Distinguishes Prostatic Intraepithelial Neoplasia and Prostate Cancer from Benign Prostate Hyperplasia. ( Appolonova, SA; Brito, A; Enikeev, DV; Fodor, M; Lartsova, EV; Lerner, YV; Lyundup, AV; Markin, PA; Mikhajlov, VY; Moskaleva, N; Potoldykova, NV; Shpot, YV, 2020) |
| "Post-treatment sarcosine levels were elevated in 266 (52%) patients and highly elevated (≥200 nmol/L) in 71 (13%) patients." | 1.48 | Post-treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer. ( Adam, V; Cernei, N; Gumulec, J; Heger, Z; Lackova, Z; Pacik, D; Plevova, M; Raudenska, M; Sorokac-Kubolkova, A; Strmiska, V; Zitka, O, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Markin, PA | 1 |
| Brito, A | 1 |
| Moskaleva, N | 1 |
| Fodor, M | 1 |
| Lartsova, EV | 1 |
| Shpot, YV | 1 |
| Lerner, YV | 1 |
| Mikhajlov, VY | 1 |
| Potoldykova, NV | 1 |
| Enikeev, DV | 1 |
| Lyundup, AV | 1 |
| Appolonova, SA | 1 |
| Gumulec, J | 1 |
| Raudenska, M | 1 |
| Pacik, D | 1 |
| Plevova, M | 1 |
| Sorokac-Kubolkova, A | 1 |
| Lackova, Z | 1 |
| Cernei, N | 1 |
| Strmiska, V | 1 |
| Zitka, O | 1 |
| Heger, Z | 1 |
| Adam, V | 1 |
| Kumar, D | 1 |
| Gupta, A | 1 |
| Mandhani, A | 1 |
| Sankhwar, SN | 1 |
3 other studies available for sarcosine and Prostatic Hyperplasia
| Article | Year |
|---|---|
Plasma Sarcosine Measured by Gas Chromatography-Mass Spectrometry Distinguishes Prostatic Intraepithelial Neoplasia and Prostate Cancer from Benign Prostate Hyperplasia.
Topics: Aged; Aged, 80 and over; Biomarkers; Biomarkers, Tumor; Biopsy; Gas Chromatography-Mass Spectrometry | 2020 |
Post-treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Biomarkers; Humans; Male; Neoplasm Recurrence, Local; Posto | 2018 |
NMR spectroscopy of filtered serum of prostate cancer: A new frontier in metabolomics.
Topics: Aged; Biomarkers, Tumor; Biopsy; Citric Acid; Diagnosis, Differential; Digital Rectal Examination; G | 2016 |